ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics

References

• MattickRDigiustoEDoranCNational Evaluation of Pharmacotherapies for Opioid Dependence: Report of Results and RecommendationsSydney, AustraliaNational Drug and Alcohol Research Centre2001
   Google Scholar
• CrettolSDeglonJJBessonJABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatmentClin Pharmacol Ther200680666868117178267
   PubMed Web of Science ®Google Scholar
• DyerKRFosterDJWhiteJMSomogyiAAMenelaouABochnerFSteady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationshipsClin Pharmacol Ther199965668569410391674
   PubMed Web of Science ®Google Scholar
• DyerKRWhiteJMPatterns of symptom complaints in methadone maintenance patientsAddiction19979211144514559519488
   PubMed Web of Science ®Google Scholar
• FosterDJRSomogyiAAWhiteJMBochnerFPopulation pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patientsBr J Clin Pharmacol200457674275515151520
   PubMed Web of Science ®Google Scholar
• BellJBurrellTIndigDGilmourSCycling in and out of treatment; participation in methadone treatment in NSW, 1990–2002Drug Alcohol Depend2006811556115993552
   PubMed Web of Science ®Google Scholar
• Australian Institute of Health and WelfareStatistics on Drug Use in Australia 2006Canberra, AustraliaAustralian Institute of Health and Welfare2007
   Google Scholar
• SomogyiAABarrattDTCollerJKPharmacogenetics of opioidsClin Pharmacol Ther200781342944417339873
   PubMed Web of Science ®Google Scholar
• EapCBCrettolSRougierJSStereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizersClin Pharmacol Ther200781571972817329992
   PubMed Web of Science ®Google Scholar
• UehlingerCCrettolSChassotPIncreased (R)-methadone plasma concentrations by quetiapine in cytochrome P450s and ABCB1 genotyped patientsJ Clin Psychopharmacol200727327327817502774
   PubMed Web of Science ®Google Scholar
• FonsecaFde la TorreRDiazLContribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and responsePLoS One201165e1952721589866
   PubMed Web of Science ®Google Scholar
• CollerJKJoergensenCFosterDJLack of influence of CYP2D6 genotype on the clearance of (R)-, (S)- and racemic-methadoneInt J Clin Pharmacol Ther200745741041717725248
   PubMed Web of Science ®Google Scholar
• HassanHEMyersALCoopAEddingtonNDDifferential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: in vitro and in vivo evaluationJ Pharm Sci200998124928494019370547
   PubMed Web of Science ®Google Scholar
• TournierNChevillardLMegarbaneBPirnaySScherrmannJMDeclevesXInteraction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)Int J Neuropsychopharmacol2009111
   Web of Science ®Google Scholar
• LinJHYamazakiMClinical relevance of P-glycoprotein in drug therapyDrug Metab Rev200335441745414705869
   PubMed Web of Science ®Google Scholar
• LinJHYamazakiMRole of P-glycoprotein in pharmacokinetics: clinical implicationsClin Pharmacokinet2003421599812489979
   PubMed Web of Science ®Google Scholar
• TournierNDeclevesXSaubameaBScherrmannJMCisterninoSOpioid transport by ATP-binding cassette (ABC) transporters at the blood-brain barrier: implications for neuropsychopharmacologyCurr Pharm Des201117262829284221827411
   PubMed Web of Science ®Google Scholar
• CollerJKBarrattDTDahlenKLoennechenMHSomogyiAAABCB1 genetic variability and methadone dosage requirements in opioid-dependent individualsClin Pharmacol Ther200680668269017178268
   PubMed Web of Science ®Google Scholar
• CrettolSDeglonJJBessonJNo influence of ABCB1 haplotypes on methadone dosage requirementClin Pharmacol Ther2008835668669 author reply 669–67018043693
   PubMed Web of Science ®Google Scholar
• LevranOO'HaraKPelesEABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependenceHum Mol Genet200817142219222718424454
   PubMed Web of Science ®Google Scholar
• CollerJKBarrattDTSomogyiAAResponse to “No influence of ABCB1 haplotypes on methadone dosage requirement”Clin Pharmacol Ther2008835669670
   Web of Science ®Google Scholar
• CrettolSBessonJCroquette-KrokarMAssociation of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatmentProg Neuropsychopharmacol Biol Psychiatry20083271722172718687376
   PubMed Web of Science ®Google Scholar
• OertelBGKettnerMScholichKA common human micro-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of painJ Biol Chem2009284106530653519116204
   PubMed Web of Science ®Google Scholar
• KasaiSIkedaKPharmacogenomics of the human micro-opioid receptorPharmacogenomics20111291305132021919606
   PubMed Web of Science ®Google Scholar
• LötschJSkarkeCWietingJModulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug actionClin Pharmacol Ther2006791728916413243
   PubMed Web of Science ®Google Scholar
• CampaDGioiaATomeiAPoliPBaraleRAssociation of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain reliefClin Pharmacol Ther200883455956617898703
   PubMed Web of Science ®Google Scholar
• HurleyMWhiteJChaddertonTGuide for Pharmacists: Addiction Treatment and Maintenance Pharmacotherapy (Methadone and Buprenorphine) Programs in South AustraliaAdelaide, AustraliaDrug and Alcohol Services South Australia2010
   Google Scholar
• NSW Department of HealthNew South Wales Opioid Treatment Program: Clinical Guidelines for Methadone and Buprenorphine Treatment of Opioid DependenceNorth Sydney, AustraliaMental Health and Drug and Alcohol Office, NSW Department of Health2006
   Google Scholar
• CascorbiIGerloffTJohneAFrequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjectsClin Pharmacol Ther200169316917411240981
   PubMed Web of Science ®Google Scholar
• CollerJKBeardsleyJBignoldJLack of association between the A118G polymorphism of the mu opioid receptor gene (OPRM1) and opioid dependence: A meta-analysisPharmacogenomics Pers Med200921919
   Google Scholar
• StephensMDonnelyPA comparison of Bayesian methods for haplotype reconstructionAm J Hum Genet20037351162116914574645
   PubMed Web of Science ®Google Scholar
• StephensMSmithNDonnelyPA new statistical method for haplotype reconstruction from population dataAm J Hum Genet200168497898911254454
   PubMed Web of Science ®Google Scholar
• AirdREThomsonMMacphersonJSThurstonDEJodrellDIGuichardSMABCB1 genetic polymorphism influences the pharmacology of the new pyrrolobenzodiazepine derivative SJG-136Pharmacogenomics J20088428929617563765
   PubMed Web of Science ®Google Scholar
• SalamaNNYangZBuiTHoRJMDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cellsJ Pharm Sci200695102293230816883550
   PubMed Web of Science ®Google Scholar
• GowJMHodgesLMChinnLWKroetzDLSubstrate-dependent effects of human ABCB1 coding polymorphismsJ Pharmacol Exp Ther2008325243544218287207
   PubMed Web of Science ®Google Scholar
• Kimchi-SarfatyCOhJMKimIWA “silent” polymorphism in the MDR1 gene changes substrate specificityScience2007315581152552817185560
   PubMed Web of Science ®Google Scholar
• MoritaNYasumoriTNakayamaKHuman MDR1 polymorphism: G2677T/A and C3435T have no effect on MDR1 transport activitiesBiochem Pharmacol200365111843185212781336
   PubMed Web of Science ®Google Scholar
• DoehringAHentigNGraffJGenetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitutionPharmacogenet Genomics200919640741419373123
   PubMed Web of Science ®Google Scholar
• LevranOPelesEHamonSNerve growth factor beta polypeptide (NGFB) genetic variability: association with the methadone dose required for effective maintenance treatmentPharmacogenomics J312011 [Epub ahead of print.]
   Web of Science ®Google Scholar
• FonsecaFGratacosMEscaramisGResponse to methadone maintenance treatment is associated with the MYOCD and GRM6 genesMol Diagn Ther201014317117820560679
   PubMed Web of Science ®Google Scholar
• OnedaBCrettolSBochudMbeta-Arrestin2 influences the response to methadone in opioid-dependent patientsPharmacogenomics J201111425826620514076
   PubMed Web of Science ®Google Scholar
• LotschJPrussHVehRWDoehringAA KCNJ6 (Kir3.2, GIRK2) gene polymorphism modulates opioid effects on analgesia and addiction but not on pupil sizePharmacogenet Genomics201020529129720220551
   PubMed Web of Science ®Google Scholar
• HungCCChiouMHHuangBHImpact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patientsPharmacogenomics201112111525153321902500
   PubMed Web of Science ®Google Scholar